May 3 |
Biomea Fusion GAAP EPS of -$1.09 misses by $0.02
|
May 2 |
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
|
Apr 2 |
Biomea Fusion drops as JPMorgan downgrades on data for lead asset
|
Apr 1 |
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
Apr 1 |
Biomea Fusion GAAP EPS of -$0.98
|
Apr 1 |
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
|
Apr 1 |
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
|
Mar 7 |
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
|
Mar 6 |
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
|
Mar 1 |
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|